Mach7 Reports Q1 FY26 Business Update
Key points
- CARR of A$29.6M; ARR Run Rate of A$23.5M at 30 September 2025
- Q1 FY26 Sales orders of A$2.6M (TCV)
- Initial limited go-live of Phase 1 of VHA National Teleradiology Project
- Leadership renewal with several key appointments including new VP, Sales
Full summary
Mach7 Technologies reported its Q1 FY26 business update, highlighting CARR of A$29.6M, ARR Run Rate of A$23.5M, and Q1 FY26 Sales orders of A$2.6M (TCV). The company also announced the initial limited go-live of Phase 1 of the VHA National Teleradiology Project, a major regulatory milestone with the successful submission of its Medical Device Regulation (MDR) Technical File, and several leadership changes including the appointment of a new VP Sales and the return of founder Ravi Krishnan as Advisor to the CEO. Mach7 CEO Teri Thomas stated that Q1 FY26 has been an important quarter for the company as they lowered their cost base, completed critical go-lives, and made deep organisational changes to strengthen execution. The company now has the visibility, leadership, and structure in place to drive sustained momentum and deliver a solid rebound through the second half of FY26.
Guidance
Mach7 is currently generating A$23.5M in ARR, a run rate calculated by annualising the revenue earned from Subscription and Maintenance and Support fees. ARR will grow as new customers achieve First Productive Use and existing customers expand, renew at increased rates or achieve First Productive Use on add-ons.
Outlook
During Q2 FY26, the focus will remain on the completion and implementation of the strategic review as the company accelerates the delivery of innovation and executes a full commercial transformation.
Summary generated by a large language model. Please interpret with care.